These findings are consistent with previous research that has established Ki-67 as a marker of proliferation and aggressive tumor biology, particularly in high-grade and biologically aggressive breast cancer subtypes, such as HER2-positive and triple-negative cancers [13,14]. Here, ERBB2 is linked to breast carcinoma.